Skip to main content
. 2022 Jan 13;9(2):998–1007. doi: 10.1002/ehf2.13725

Figure 1.

Figure 1

Circ_0001206 alleviates hypoxia/reoxygenation (H/R)‐induced cardiomyocyte injury in myocardial infarction (MI). (A) Expression of circ_0001206 in H9C2 cells was examined via quantitative real‐time polymerase chain reaction (RT‐qPCR) under hypoxia for 0, 1, 6 and 24 h. Expression of circ_0001206 in MI mouse model was detected. (B) RT‐qPCR detected the level of circ_0001206 and linear‐CRKL in RNase R‐treated H9C2 cells. (C) RT‐qPCR examined the stability of circ_0001206 and linear‐CRKL in Act D‐treated H9C2 cells. (D) Circ_0001206 existence was examined in H9C2 cells using RT‐qPCR. Divergent primers amplified circ_0001206 in cDNA but not in genomic DNA (gDNA). (E) RT‐qPCR detected the efficacy of pcDNA3.1‐circ_0001206 in H/R‐treated H9C2 cells. (F) CCK‐8 assay detected the cell viability under H/R treatment in circ_0001206‐overexpressed H9C2 cells. (G) Western blot detected protein levels of Bax, Bcl‐2, cleaved caspase‐3, and cleaved caspase‐9 in H/R‐induced H9C2 cells after the enhancement of circ_0001206 (n = 3). *P < 0.05, **P < 0.01.